Passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic metabolic disorders

Agios (NASDAQ: AGIO) is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. Based on results from the Phase I/II AG-221 AML-001 study, the FDA has approved enasidenib (IDHIFA) as the first oral targeted therapy for adult patients with relapsed or refractory acute myeloid leukemia and an IDH2 mutation. All Agios programs focus on genetically identified patient populations, leveraging the company’s knowledge of metabolism, biology and genomics.

Year Invested: 2008
Location: Cambridge, Mass.

Recent News

August 8, 2017
Agios Reports Second Quarter 2017 Financial Results

August 3, 2017
Agios to Present at the Canaccord Genuity 37th Annual Growth Conference Thursday, August 10, 2017

August 1, 2017
FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation

Read More News

Associated Team Members

Kevin Starr

Craig Muir
Partner/Chief Technology Officer

Cary Pfeffer, M.D.